TRANSPARENCY F R CHANGE Good Governance For Medicines Global Stakeholders Meeting 3-5 December 2007, Bangkok, Thailand The Ministry of Public Health, Thailand MEETING GUIDE
TRANSPARENCY F R CHANGE
Good Governance For Medicines Global Stakeholders Meeting3-5 December 2007, Bangkok, Thailand
The Ministry of Public Health, Thailand
MEETINGGUIDE
CONTENTS
Welcome to the Good Governance for Medicines Stakeholders Meeting
• WelcomebyWorldHealthOrganization 7
• WelcometoBangkok 9
• WelcometoTheMontienHotelBangkok 11
Professional Programme
• MeetingAgenda 13
• PlenarySessions’Objectives 18
• WorkshopSessions’Objectives 22
Networking Events
• WelcomeCocktail 29
• OffSiteDinner 29
Speakers
• SpeakerProfilesandPhotos 31
EvaluationForm 63
Notes 71
7
WELCOMEBYTHEWORLDHEALTHORGANIZATION
DearParticipants,
IwouldliketopersonallywelcomeyoutotheGlobalStakeholdersmeetingoftheWHO
GoodGovernanceforMedicinesprogramme.
Thisistheprogramme's2ndglobalstakeholdersmeetingthatWHOhasorganized,
andwearedelightedtoseesomanyofyouhereinBangkok.Thisisarealsignthat
transparency in the pharmaceutical sector is an area of increasing interest for our
stakeholdersandthatmoreandmorecountriesarekeentoworkinthischallenging,
butrewardingarea.
Thethemeofthemeetingis"TransparencyforChange".Icanpromiseyouthat
thenextthreedayswillbefulloflearningandnetworkingopportunitiesforyouall,
withtheopportunitytoreviewexperiencesandtolearnfromeachother.Wehave
animpressivelineupofeminentspeakerswhowillsharetheirinsightsintotoday’s
issuesandchallenges.Ourspeakerswillnotonlyincreaseourknowledgeoftheworld
ofgoodgovernanceingeneral,andofthemedicinesareainparticular,butourinten-
tionisthattheywillalsomotivateustoincreaseoureffortstoimprovethesituation
inthepharmaceuticalsectorwhenweleaveBangkokandreturntoourvariouswork
settings.Thegoaliseventuallytoofferaprocessforlong-lastingchange-forallof
ustomobilizea"callforaction"tomeetthechallengesahead,andultimatelytohelp
makequalityessentialmedicinesaccessibleandaffordableforall.
Having launched itsprogramme in2004,WHOremainscommittedtopromoting
goodgovernanceformedicinesinthefuture.Itwilldosobyfurtherrefiningitspolicy
andtechnicalguidanceandbyprovidingtechnicalsupporttocountrieswhorequestit.
WHOwillalsocontinuetoactasafacilitatortobringallthekeystakeholderstogether
onaregularbasistoprovidethisplatformtoexchangeexperiencesandnetwork.
Wewouldliketothankourhosts,theThaiMinistryofPublicHealth,aswellas
WHO’sCountryOfficeinBangkokandtheWHORegionalOfficeforSouth-EastAsiafor
8
theirvaluable support.Theconferencewouldnothavebeenpossiblewithout their
dedicationandhardworkinthelastfewmonths.
Andfinally,Ithankeveryoneforcoming-panellists,moderatorsandparticipants.
Ihopeyouhaveanenjoyableandrewardingtimewithus.Ifyouneedassistanceof
anykind,pleasecontactoneofourteammembers,whowillbemakingthemselves
knowntoyou.
Ilookforwardtomeetingyou,
DrHansV.Hogerzeil
Director
MedicinesPolicyandStandards
WorldHealthOrganization
8
9
Didyouknowthattherearemorethan10millionpeoplelivinginBangkok?
Or,didyouknowthatthelocalscallBangkok“KrungThep”whichmeanstheCityof
Angels?
Thailand’scapitalcity,Bangkok,haschangedintoamodern,excitingandsophisti-
catedcity.Itofferstovisitorsnotonlythecosmopolitanamenitiestheywouldexpect
fromotherbigcities,butalsoauniquetreasuretroveofculturalattractions.Bangkok
offersvisitorstheopportunitytoexperienceafascinatingglimpseofThailand’sgentle
cultureamidstthebustleofagreatanddynamicmetropolis.
Interestingfacts—didyouknowthat...?• Siamchangeditsnamein1939toThailand,meaning“landofthefree”.
• 75%ofthepeoplelivinginThailandareThai,14%areChineseand11%other
nationalities.
• thereare400glitteringBuddhisttemplesinBangkok.
• thereare3.8%MuslimsinThailand,0.1Hindus,0.5%Christians,0.6%other
religionsand95%Buddhists.
• BangkokhasdevelopedintooneofthemostpopularshoppinglocationsinAsia.
• Bangkokwasfoundedin1782bythefirstmonarchofthepresentChakridynasty
anditistodayaconstitutionalmonarchy.
• Skytrainfarescostbetween10Bahtand40Bahtperpersondependingonthe
distance,aboutonethirdthecostofacomparabletaxiride.
• Thailandhas3290kmofcoastline.
• taxisoutnumberprivatecars2:1inBangkokandmostjourneyscanbecompleted
forwellunder100Baht.Makesureyoutakeagenuinetaxiwithataximeter.
• oneUSdollarisequaltoapproximately30Baht.
• theThailanguageissimilartoTai,thelanguagespokenbythepeoplewholivein
SouthernChina.
• KingBhumibolAdulyadej,thebelovedkingofThailand,isgoingtobe80years
oldonDecember5th.HewasborninCambridge,Massachusetts,USA,andedu-
catedinLausanneinSwitzerland.
WELCOMETOTHEKINGDOMOFTHAILANDANDITSCAPITALBANGKOK
10
YourSmallEnglish–ThaiDictionary:
ENGLISH THAI
Goodmorning,Goodevening,Goodafternoon,Good
night,Hello
sa-wat-dee
Hello(malespeaker) sawatdeekrup
Hello(femalespeaker) sawatdee kaa
Yes chai
No mai
Mr./Miss/Mrs. khun
Howareyou? sabaideereu
Fine thanks sabaidee
Whereistherestroom? hongnamyooteenai
Iamgoingto... chan-cha-pai...
Stop yut
Howmuchdoesthiscost? nee tao-rai
Whatisthis? nee arai
Veryexpensive paengmaag
Anydiscount? lot-ra-kha-dai-mai
Pleasewrapitforme ho-hai-duai
Thebillplease geptaang
Pleasespeakslowly prot-phut-cha-cha
VeryGood di-mak
Not Good mai-di
Goodbye la gon
Seeyouagain laewphobganmai
Good luck kor hai chok dee
Sorry/excuseme kor thoad
10
11
WELCOMETOTHEMONTIENHOTELBANGKOK
TheMontienHotelBangkokislocatedintheheartofBangkok'smajorbusinessand
entertainmentdistrict,withineasywalkingdistanceofmanyoffices,shopsandnight-
spots.JustfiveminutesawayistheneareststationoftheMassTransitSystem,which
providesrapidaccesstootherpartsofthecity.Offering475roomsandsuites,includ-
ingExecutiveFloorswithprivatelounge,meetingroomsandfullyequippedbusiness
centre,thehotelisperfectlysituatedforboththebusinesstravellerandtheleisure
visitortoBangkok.
ThehotelislocatedonSurawongseRoad,yourbusinessaddressintheheartofthecity
withthemostflexiblecombinationofsuperioraccommodationandbusinessfacilities
tomeetyoureverydemand.MontienHotelBangkokisproudtoofferawidevariety
ofcuisineincludingaChineseandaEuropeanrestaurantaswellasa24-hoursInter-
nationalCoffeeShop.
ItiswithdelightthatthehotelwelcomesallparticipantstotheGoodGovernancefor
MedicinesStakeholdersMeeting,3-5thDecember2007.
HotelAddress:
54SurawongseRoad,Bangkok10500,Thailand.
Tel.:(662)233-7060-9
http://www.montien.com/bangkok/
14
TIME DAY1
08.00-08.45 Registration
08.45-09.00 OfficialOpeningbytheThaiMinistryofPublicHealth
09.00-10.15 Plenary Session 1:
Think transparency! Good Governance in the pharmaceutical sector.Room:RajmontienIV,MezzanineFacilitator:Dr.HansHogerzeil,WorldHealthOrganization
Panelists:Promoting Good Governance in the Pharmaceutical Sector, a Global ExperienceDr.GuitelleBaghdadi-Sabeti,WorldHealthOrganization
Good Governance for Medicines Programme: the Thai ExperienceDr.ChanvitTharathep,MinistryofPublicHealth,Thailand
Toward Scientific Drug Administration Mr.ChangyuanLin, StateFoodandDrugAdministration,People’sRepublicofChina
Transparency in the Governance of Bulgaria’s Pharmaceutical System – results of a case studyMrs.GerganaAndre,InternationalHealthcareandHealthInsuranceInstitute,Bulgaria
10.15-10.30 Questionsandplenarydiscussions
10.30-11.00 CoffeeBreak
11.00-12.15 Plenary Session 2:
The root of corruption. Understanding the issues to cure it!Room:RajmontienIV,MezzanineFacilitator:Dr.CliveOndari,WorldHealthOrganization
Panelists:Governance and Corruption: the Gray Area of Policy Dr.MaureenLewis,TheWorldBank
Fighting Corruption - Challenges and ThreatsMr.MartinKreutner,FederalBureauforInternalAffairs,Austria
Systems, Attitudes, and Action as Root Causes of Corruption Dr.StevenRood,AsiaFoundation,Philippines
Transparency International Global Corruption Report 2006TransparencyInternationalSecretariat,representativetobeannounced
12.15-12.30 Questionsandplenarydiscussions
15
12.30-14.00 Lunch:MontiRestaurantatthehotel
14.00-15.30 Workshops1aand1b:SeminarI&SeminarII,6thFloorBRIDGINGTHERESEARCHGAP–whatdowestillneedtoknow,andhowdowegoaboutit?
14.00-15.30 Workshops2aand2b:SeminarIII&IV,6thFloorMAXIMIZINGTHEUSEOFINTERNETTOINCREASETRANSPARENCY–how?
14.00-15.30 Workshops3aand3b:SeminarV&VI,7thFloorESTABLISHINGANATIONALGGMTASKFORCE–whatarethechallengesahead?
14.00-15.30 Workshops4aand4b:SeminarVII&VIII,7thFloorJOININGFORCESONANATIONALLEVELWITHANTI-CORRUPTIONAGENCIES–whatworks,whatdoesn’t?
15.30-16.00 CoffeeBreak
16.00-17.00 Presentations/FeedbackfromWorkshops
19.00-21.00 WelcomeReception
TIME DAY2
09.00-10.15 Plenary Session 3:
Practicing transparency! Good Governance in the health sector.Room:Montienthip,MezzanineFacilitator:Dr.HansHogerzeil,WorldHealthOrganization
Panelists:Good and Bad Practices in Good Governance and What Can Be Done toPromote Good Governance Dr.MaureenLewis,TheWorldBank
Protecting Healthcare Systems Against Fraud so that They CanBetter Protect the Health of Citizens Mr.JimGee,KPMGForensic,UnitedKingdom
Detecting and Solving System WeaknessesMr.PaulVincke,EuropeanHealthcareFraudandCorruptionNetwork,Belgium
Promoting Good Governance in Medicines: Industry’s RoleDr.EricNoehrenberg, International Federation of Pharmaceutical Manufacturers&Associations,Switzerland
10.15-10.30 Questionsandplenarydiscussions
10.30-11.00 CoffeeBreak
16
11.00-12.15 Plenary Session 4:
Keeping it together! The basic ingredients for ensuring Good
Governance.Room:Montienthip,MezzanineFacilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup
Panelists:The Ethical Dimension of Good Governance Dr.EloyAnello,NúrUniversity,Bolivia
Promoting Good Governance, the Experience of the Ministry of Health in GermanyDr.SonjaFüsser,MinistryofHealth,Germany
A National Strategy for Ensuring Good GovernanceMrs.FatumaSichale,Anti-CorruptionCommission,Kenya
12.15-12.30 Questionsandplenarydiscussions
12.30-14.00 Lunch:MontiRestaurant(Wewillcollectquestionsforthenextmorning’ssession.)
14.00-15.30 Workshops5aand5b:SeminarI&SeminarII,6thFloorCANYOUBREAKTHROUGHTHEGIFT-GIVINGCULTURE?–howdowebringtransparencytothegreyzone?
14.00-15.30 Workshops6aand6b:SeminarIII&IV,6thFloorDEFININGINTEGRITY–howdoweraisethestandardsandmotivatepermanentchange?
14.00-15.30 Workshops7aand7b:SeminarV&VI,7thFloorWHATRADICALCHANGESWILLTRANSPARENCYBRINGTOTHEPHARMACEUTICALWORLD?•whoaretheplayers?•whatwillbetheimpactonpublichealth?
14.00-15.30 Workshops8aand8b:SeminarVII&VIII,7thFloorSERVINGTRANSPARENCY!HowcanWHObeofbetterservicewhenfacilitatingGGMprogrammeimplementation?Giveideasandfeedback.
15.30-16.00 CoffeeBreak
16.00-17.00 Presentations/FeedbackfromWorkshops
18.30-21.00 Off Site Networking Dinner
17
TIME DAY3
09.00-10.30 Plenary Session 5:
Questioning transparency.
Our panelists respond to you!Room:Montienthip,MezzanineFacilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup
10.30-11.00 CoffeeBreak
11.00-12.15 Plenary Session 6:
Rolling out transparency. What is your role?Room:Montienthip,MezzanineFacilitator:Dr.CliveOndari,WorldHealthOrganization
Panelists:USAID Support for Good Governance in MedicinesMr.AnthonyBoni,USAID,UnitedStatesofAmerica
Civil Society Organizations: What is Their Role in Promoting Transparency?Mrs.CaroleBelisario,ProcurementWatchInc.,Philippines
How can the academia support the global efforts to promote transparency and good governance?Dr.NiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand
The role of development institutions in promoting good governance in the pharmaceutical sectorDr.ZafarMirza,WHORegionalOfficefortheEasternMediterranean
12.15-12.30 Questionsandplenarydiscussions
OfficialClosingbytheThaiMinistryofPublicHealth
12.30-14.00 Lunch:MontiRestaurant
18
Session1:Thinktransparency!GoodGovernanceinthepharmaceuticalsector.Facilitator:Dr.HansHogerzeil,WHO,Switzerland
Panellists:
•Dr.GuitelleBaghdadi-Sabeti,WHO,Switzerland
•Dr.ChanvitTharathep,MinistryofPublicHealth,Thailand
•Mr.ChangyuanLin,StateFoodandDrugAdministration,People'sRepublicofChina
•Mrs.GerganaAndre,InternationalHealthcareandHealthInsuranceInstitute,Bulgaria
Theimportanceoftransparencyandaccountabilityinpharmaceuticalsystemsis in-
creasinglyrecognizedbythevariouskeyplayersatthecountryandinternationallev-
els.Recentinitiatives,whetheraimingatimprovinggoodgovernanceortacklingcor-
ruptionperse,provideconcreteevidence.Theseincludeglobalinitiativessuchasthe
WHOGoodGovernanceforMedicinesprogramme,aswellaspracticalcountryapplica-
tions.Duringthissession,experiencesinreflectingonandpromotingtransparencywill
beshared,togetherwithlessonslearnttodate.
Session2:Therootofcorruption.Understandingtheissuestocureit!Facilitator:Dr.CliveOndari,WHO,Switzerland
Panellists:
•Dr.MaureenLewis,WorldBank
•Mr.MartinKreutner,BureauofInternationalAffairs,FederalMinistryofInterior,Austria
•TransparencyInternationalSecretariat,representativetobeannounced
•Mr.StevenRood,AsiaFoundation,Philippines
Corruptionisaworld-wideproblem,existinginbothhigh-andlow-incomecountries.
Itisrecognizedasthesinglegreatestobstacletosocialandeconomicdevelopment.
Corruption erodes the institutional capacity of governments, increases the cost of
PLENARYSESSIONS’OBJECTIVES
19
businessandisdemeaningforpoorpeople,worseningtheirfinancialburden.Thisses-
sionwillaimatdefiningcorruption,andhighlightitscausesaswellasitsnegative
impact.
Session3:Practicingtransparency!GoodGovernanceinthehealthsector.Facilitator:Dr.HansHogerzeil,WHO,Switzerland
Panellists:
•Dr.MaureenLewis,WorldBank
•Mr.JimGee,KPMGForensic,UnitedKingdom
•Mr.PaulVincke,EuropeanHealthcareFraudandCorruptionNetwork(EHFCN),Belgium
•Dr.EricNoehrenberg,InternationalFederationofPharmaceuticalManufacturers&
Associations,Switzerland
Thepharmaceuticalsectorisanintegralelementofhealthsystems.Activitiesinmedi-
cinesregulationandsupplyhaveadirectimpactonhealthsystems'functioningand
viceversa.Effortstopromotegoodgovernanceinthepharmaceuticalsectorandinthe
healthsectorasawholeneedtocomplementeachother.Inthissession,panelistswill
shedadditionallightonhowhealthcaresystemscanbeprotectedfromabuse.
Session4:Keepingittogether!ThebasicingredientsforensuringGoodGovernance.Facilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup
Panellists:
•Dr.EloyAnello,NùrUniversity,Bolivia
•Dr.SonjaFüsser,MinistryofHealth,Germany
•Mrs.FatumaSichale,Anti-CorruptionCommission,Kenya
Good governance programmes require a combination of various, complementary
20
components.These include:anethical frameworkandcodeofconduct;established
anti-corruption legislation; regulationsandadministrativeprocedures;collaboration
mechanismsbetweenexistinganti-corruptioninitiatives;whistle-blowingmechanisms;
andsanctionsforreprehensibleacts.Panellistswillshareexperiencesinimplementing
someofthesecomponentsatthecountryandgloballevels.
Session5:Questioningtransparency.Ourpanellistsrespondtoyou!Facilitator:Dr.KerstinLeitner,WHO,GGMGlobalAdvisoryGroup
Inthissession,yourpanellistswillreplytoyourquestionsthatmayhaveremainedun-
answeredfromthepreviousplenarysessions,ornewonesraisedduringtheafternoon
workshopsandinformaldiscussionsamongparticipants.Pleasetaketimetowriteyour
questionsandplacethemintheboxprovided.
Session6:Rollingouttransparency.Whatisyourrole?Facilitator:Dr.CliveOndari,WHO,Switzerland
Panellists:
•Mr.AnthonyBoni,USAID,UnitedStatesofAmerica
•Mrs.CaroleBelisario,ProcurementWatchInc.,Philippines
•Dr.NiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand
•Dr.ZafarMirza,WHORegionalOfficefortheEasternMediterranean,Egypt
Stakeholders in thepharmaceutical sectoraremanyanddiverse. They includedrug
regulatoryauthoritiesandmedicinessupplymanagers,civilsocietyorganizationsand
academia,thepublicandtheprivatesectors,donorsandrecipientgovernments.Each
onehasaroleandeventuallytheiractionswillbringchanges.Wemayhavedifferent
roles,butweshouldaimtomakeactivitiescomplementary intheglobalefforts to
increaseaccesstoqualitymedicines.Inthissessionwewilldiscusstherolesofeach
stakeholderinrollingouttransparency,andacallforactionwillbemade.
22
WORKSHOPSESSIONS’OBJECTIVES
DAY1 MODERATORS BACKGROUNDANDOBJECTIVES
WORKSHOP1(aandb):
BRIDGINGTHERESEARCHGAP–what do we still needtoknow,andhowdowegoaboutit?
Workshop1.a:AbuBakarAbdulMajeed,UniversityofTechnologyMara,MalaysiaPaulVincke,EuropeanHealthcareFraudandCorruptionNetwork(EHFCN),Belgium
Workshop1.b:NiyadaKiatying-Angsulee,ChulalongkornUniversity,ThailandClive Ondari,WHOHeadquarters,Geneva
Corruptpracticesinthepharmaceuticalsector are being increasingly docu-mented. For example, Transparency In-ternational’s Global Corruption Report2006consolidatesalargeamountoftheexisting knowledge. Still, the scale ofthesepracticesandtheirimpact(healthandeconomic)isnotyetfullyknown.
The objective of this workshop is todefine the areas where more researchwill be needed in order to betterprevent corrupt practices and promotegoodgovernanceinthepharmaceuticalsector.
Attheendofeachday:Presentation/feedbackfromworkshops.Note:8minutespergroup
Each workshop has a PC for notesand to prepare the short PowerPointpresentation which will be the resultofthediscussions.Themoderatorswillpresentfeedbackfromtheirgroup.
WORKSHOP2(aandb):
MAXIMIZINGTHEUSEOFINTERNETTOINCREASETRANSPARENCY-how?
Workshop2.a:ChanvitTharathep,MinistryofHealth,ThailandSriSuryawati,GadjahMadaUniversity,Indonesia
Workshop2.b:Eshetu Wondemagegnehu,WHOConsultant,EthiopiaSirinartVasanavathana,OfficeofFoodandDrugAdministration,Thailand
Theinternetisaremarkableanduniquetooltopromotetransparency.Moreandmore medicines regulatory agenciespost on their website the informationthatneeds tobepubliclyavailable,aswell as the details of procedures foradministrativeprocesses.
Theobjectiveofthisworkshopistolearnfromcountriesthathavecomprehensiveinternet services that aim to promotetransparency in the pharmaceuticalsector.
23
DAY1 MODERATORS BACKGROUNDANDOBJECTIVES
WORKSHOP3(aandb):
ESTABLISHINGANATIONALGGMTASKFORCE–whatarethechallengesahead?
Workshop3.a:RosminahMohd.Din,MinistryofHealth,MalaysiaNazaritaTacandong,WHORegionalOfficefortheWesternPacific,Philippines
Workshop3.b:CaroleBelisario,ProcurementWatch,Inc.,PhilippinesSocorro Escalante,WHO,Philippines
Governments must delegate the implementation of a Good GovernanceforMedicines programme to an appro-priate implementing agency or taskforce. If such an agency or task forcedoes not already exist, it needs to beestablishedwiththeappropriatehumanandfinancialresources.
The objective of this workshop is tolearnfromcountriesthathaverecentlysetupaGoodGovernanceforMedicinesimplementingagencyonhowbesttogoaboutit.
Attheendofeachday:Presentation/feedbackfromworkshops.Note:8minutespergroup
Each workshop has a PC for notesand to prepare the short PowerPointpresentationwhichwillbetheresultofthediscussions.Themoderatorswillthenpresentfeedbackfromtheirgroup.
WORKSHOP4(aandb):
JOININGFORCESONANATIONALLEVELWITHANTI-CORRUPTIONAGENCIES–whatworks,whatdoesn’t?
Workshop4.a:EloyAnello,NúrUniversity,BoliviaWilfred Dodoli,WHO,Malawi
Workshop4.b:Maria Miralles,ManagementSciencesforHealth,USA.Moses Chisale,WHORegionalOfficeforAfrica,Gabon
Mostcountrieshavealreadyestablishednational anti-corruption agencies aspartoftheireffortstotacklecorruptionwithacross-sectoralperspective.Theseagenciescanprovidestrongsupporttonational Good Governance for Medicines programmes. It is useful to establishcollaboration mechanisms with them,notonlytogaintheirsupportbutalsotoavoidduplicationofefforts.
The objective of this workshop is toidentify types of existing nationalagencies that can help national GoodGovernance for Medicines programmesand to define the best approach forestablishingcollaborationmechanisms.
24
DAY2 MODERATORS BACKGROUNDANDOBJECTIVES
WORKSHOP5(aandb):
CANYOUBREAKTHROUGHTHEGIFT-GIVINGCULTURE?-howdowebringtransparencytothegreyzone?
Workshop5.a:SirinartVasanavathana,OfficeofFoodandDrugAdministration,ThailandWilliamMfuko,WHO,Cambodia Workshop5.b:MosesChisale,WHORegionalOfficeforAfrica,GabonNazaritaTacandong,WHORegionalOfficefortheWesternPacific,Philippines
Gift-giving in the working environment iscommonpracticeinmanysettings.Onthe one hand, it is a way of showingappreciation of collaboration betweenstaff or institutions. On the other,studiesbysocialscientistshaveprovedthat gift-giving also creates a sense of indebtedness and reciprocity, and caninfluencedecision-makingprocesses.
The objective of this workshop isto review the impact of gift-givingpractices, and reflect on how thesepracticescanbechangedovertime.
Attheendofeachday:Presentation/feedbackfromworkshops.Note:8minutespergroup
Each workshop has a PC for notesand to prepare the short PowerPointpresentation which will be the resultofthediscussions.Themoderatorswillpresentfeedbackfromtheirgroup.
WORKSHOP6(aandb):
DEFININGINTEGRITY–howdoweraisethe standards and motivatepermanentchange?
Workshop6.a:ChanvitTharathep,MinistryofHealth,ThailandEloyAnello,NúrUniversity,Bolivia
Workshop6.b:AbuBakarAbdulMajeed,UniversityofTechnologyMara,MalaysiaClive Ondari,WHOHeadquarters,Geneva
Overcoming corruption in the pharma-ceutical sector requires a long-term strategy and the implementation ofgood governance. Experience hasshown that its impact will depend onthe coordinated application of twobasicstrategies,oneestablishinganti-corruption laws and regulation for thepractice of pharmacy, and the otherbuildinginstitutional integritythroughthe promotion of moral values andethicalpractices.
This workshop will focus on thesecond strategy: building institutionalintegrity.
25
DAY2 MODERATORS BACKGROUNDANDOBJECTIVES
WORKSHOP7(aandb):
WHATRADICALCHANGESWILLTRANSPARENCYBRINGTOTHEPHARMACEUTICALWORLD?- who are the players?-whatwillbetheimpactonpublichealth?
Workshop7.a:Eshetu Wondemagegnehu,WHOConsultant,EthiopiaNiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand
Workshop7.b:JimGee,KPMGForensic,UnitedKingdomCaroleBelisario,ProcurementWatch,Inc.,Philippines
Having a vision of what a country orthe whole world would look like with acorrupt-freepharmaceutical sector isessential to designing a national Good GovernanceforMedicinesprogramme.Italso helps in acquiring themotivationand the drive to address an issue that isoftenperceivedasataboosubjectortoodifficulttotackle.
The objective of this workshop is todevelopaclearvisionofacorrupt-freepharmaceuticalsectorandfindwaystocreatethemotivationamongkeyplayerstoactuponit.
Attheendofeachday:Presentation/feedbackfromworkshops.Note:8minutespergroup
Each workshop has a PC for notesand to prepare the short PowerPointpresentation which will be the resultofthediscussions.Themoderatorswillpresentfeedbackfromtheirgroup.
WORKSHOP8(aandb):
SERVINGTRANSPARENCY!-HowcanWHObeofbetterservicewhen facilitating theGGMprogrammeimplementation?Giveyourideasandfeedback.
Workshop8.a:Maria Miralles,ManagementSciencesforHealth(Virginia,USA)BudionoSantoso,WHORegionalOfficefortheWesternPacific
Workshop8.b:TsetsegmaaSanjjav,HealthSciencesUniversityofMongolia ZafarMirza,WHORegionalOfficefortheEasternMediterranean,Egypt
Since WHO established the GoodGovernance for Medicines programmein2004,amodeloperatingprocessanda technicalpackage for countrieshavebeendeveloped.Still,WHOisawarethatithasembarkedonalearningprocess,and its policies and technical packagewillneedtobefurtherrefinedovertheyears.
The objective of this workshop is toreflect on WHO’s work to date in thisarea and make recommendations on how it can better support countriesin implementing national GGMprogrammes.
29
Monday 3rd December, 19.00 - 21.00
Venue:MontienthipRoomattheMontienHotel
Weinviteyoutojoinusforawelcomereception.Thisistheperfectopportunityto
meeteveryoneparticipatinginthemeetingandanexcellentnetworkingopportunity
toexchangeideas,shareexperiencesanddiscusstheoutcomeoftheprofessionalpro-
grammeofthefirstday.
OFFSITEDINNER:GRANDCHAOPHRAYACRUISE
Tuesday 4th December,DeparturefromtheMontienHotel18.30.
WearedelightedtoinviteyouforacruisealongtheChaophrayariver,theprincipal
riverofThailand,whichisregardedasthebloodlineoftheThaipeople.MuchofThai
historycanbetracedalongitsbanks.OnbothsidesoftheChaophrayariver,atourist
canseemagnificenttemplesandarchitecturalbuildings,includingtheFirstPresby-
terianChurch,theRoyalThaiNavyDockyard,theThaiMaritimeNavigationCompany,
theOldCustomsHouse,WatPrayunwong,WatArun,theGrandPalace,WatRakhang
Kositaram,andtheRoyalBoatHouse.
Wewillenjoyawonderfulbuffetdinner,accompaniedbylivemusicinthelovely
atmosphereofthecityofBangkok.
AGENDA
Checkintime: 18:45pmatRiverCityPier#1(Siphraya/charoenkrungsoi30)
Cruisingtime: 19:00pmto21:00pm
WELCOME!
WELCOMECOCKTAIL
32
Name: Prof. Abu Bakar Abdul Majeed
Institution: FacultyofPharmacy,UniversitiTeknologiMARA(UiTM)
Country: Malaysia
AbuBakarAbdulMajeedobtainedhisBachelorofPharmacydegreefromAl-ZagazigUniver-
sity,Egypt,in1983,PhDinNeurophysiologyfromSheffieldUniversityin1988andMasters
inBusinessAdministration(MBA)fromUniversitiSainsMalaysiain1996.
In1997AbuBakarjoinedtheInstituteofIslamicUnderstandingMalaysia(IKIM)as
seniorFellowattheCentreforEconomics,SocialScienceandTechnology.Hewrotefort-
nightlyintheSaturdayForumcolumnoftheNewStraitsTimesbetween1997-2002.In
2002AbuBakarwasawardedtwofellowships,onetodoresearchon ‘Bioethics’atthe
CentreforEuropeanIntegration(ZEI)inBonn,Germany,andtheotheranindividualin-
ternationalvisitor’sprogrammeon‘ReligionandSociety’bytheUSStateDepartmentin
September–October.
InFebruary2002AbuBakarwasappointedasProfessor,FacultyofPharmacy,Universiti
TeknologiMARA(UiTM),ShahAlam,andon1.9.2002asDeanoftheFaculty,UiTM,In
January2004,hewasmade FoundingChairmanof Collegeof Science and Technology,
comprising12science-basedfacultiesatUiTM,includingmedical,engineeringandapplied
sciences.
Hehaswrittenthebookentitled,‘MakingtheBestofBothWorlds–volume1:Faith
andScience’and‘MakingtheBestofBothWorlds–volume2:HeavenandEarth.’Among
thetitleseditedare:‘IslamandDevelopmentinAsia’,IslamicWorldandEurope–Some
Issues’,‘Bioethics–EthicsintheBiotechnologyCentury’,‘TheConceptandOperationsof
IslamicMedicine’,‘IslamandPreventiveMedicine’,‘IslamandMultimedia’,‘Enhancingthe
UnderstandingofIslamfortheMedia’,and‘NewKnowledge–R&DintheIslamicWorld.’
AbuBakarismarriedtoBalkhisOthman.Theyhavetwoboys,AbdulAzeemandAbdul
Azeez,andtwingirls,AisyahandAtikah.Inhisleisuretime,AbuBakarenjoystravelling,
sportsandphotography.
33
Name: Mrs. Gergana Andre
Institution: InternationalHealthcareandHealthInsuranceInstitute
Country: Bulgaria
Mrs.GerganaAndrehasaMastersdegreeinPharmacyandherpostgraduatespecial-
izationisonManagementSystemsofWholesalersandRetailPharmacies.Later,she
obtainedaMastersdegreeinHealthManagement.Currentlysheisdoingadoctorate
on“TheNationalDrugPolicyModelasaMovingFactorinHealthReforminBulgaria”.
From1995sheworkedfortheinternationalhumanitarianorganization“Pharmaciens
SansFrontières”inTajikistan,BulgariaandEgyptandlatershemovedtotheBulgarian
stateadministration.From2000to2002Mrs.Andreledthe“DrugPolicy”Department
attheMinistryofHealthinBulgariawhereshewasresponsibleforharmonizingphar-
maceuticalsectorlegislationwithEUstandards.
At presentMrs.Andre isHeadof the ”PharmaceuticalAnalysis andDrugPolicy”
department.Sheworksontheintegrationofinformationinthepharmaceuticalsec-
tor,andorganizationandparticipationininternationalprojectsinthepharmaceutical
sector, including projects under Phare Programmes, DG SANCO, participation in the
StudyofGovernanceinBulgaria’sPharmaceuticalSystembytheIRISCenter,andthe
UniversityofMaryland,USA.
34
Name: Dr. Eloy Anello
Institution: AndeanCentreofExcellenceforTraining,NurUniversity
Country: Bolivia
Dr.EloyAnelloistheNationalDirectorofNurUniversity’s“AndeanCenterofExcellence
forTraining” inSantaCruz,Bolivia. HeisalsotheGeneralAcademicandResearch
AdvisorforNurUniversity.Duringthelast25yearshehasprovidedconsultancyand
trainingservices in theareasofpublichealthandeducationtomany international
agenciesthroughoutLatinAmerica.These includePAHO/WorldHealthOrganization,
UNICEF, World Bank, Inter-American Development Bank, Kellogg Foundation, Ford
Foundation,USAID,DFID,andPlanInternational.Forthelasttwoyearshehasbeena
consultanttoWHO’sGoodGovernanceforMedicinesprogramme,developinganethical
frameworkforgoodgovernanceinthepharmaceuticalpublicsector.
35
Name: Dr. Niyada Kiatying-Angsulee
Institution: FacultyofPharmaceuticalSciences,ChulalongkornUniversity
Country: Thailand
Niyada Kiatying-Angsulee has a BSc in Pharmacy from Chulalongkorn University in
Thailand,anMSc inPharmacology fromMahidolUniversity,Thailand,andaPhD in
HealthPolicyfromtheLondonSchoolofHygieneandTropicalMedicines,University
ofLondon,UK.
Herareasofexpertiseincludedrugsystems,consumerprotection,regulation,policy
analysis,women’sdrugs,ethicsandpromotion.Sheisinvolvedinseveralnationaland
internationalacademicactivities,suchas:
• AdvisorfortheWorldHealthOrganization
• GoverningCouncilMemberofHealthActionInternationalAsiaPacific
• ExpertMemberoftheDrugCommitteeaccordingtotheDrugActB.E.2510
• MemberoftheSubcommitteeonSafetyofMedicines,underthe
DrugCommittee.
• Reviewer,ThaiHealthPromotionFund
• MemberofAdministrativeBoard,MScandPhD.SocialandAdministrative
(InternationalProgram)
• MemberoftheAdministrativeBoard,CenterforPeaceandConflictStudies,
ChulalongkornUniversity
• Chair,SocialPharmacyResearchUnit,ChulalongkornUniversity
36
Name: Dr. Guitelle Baghdadi-Sabeti
Institution: WorldHealthOrganization
Country: Switzerland
GuitelleBaghdadi-Sabetihasover15yearsexperienceinpublichealthanddevelop-
mentwork,particularlyininternationalpharmaceuticalpoliciesandpracticesaimedat
increasingaccesstogoodqualityessentialmedicines.Shehascollaboratedandprovid-
edcountrysupporttoover50MinistriesofHealth,NGOsanddevelopmentpartners.
SheholdsaMastersdegreeandaDoctorate inPharmacy from theUniversityof
GrenobleaswellasaMastersinPublicHealthfromtheUniversitéLibredeBruxelles.
Shestartedhercareerin1991inRomaniaworkingwithPharmaciensSansFrontières
andjoinedWHOin1994whereshehasworkedindifferentlocationsandcapacities.
These include theWHOofficeat theUnitedNations inNewYork, theWHOcountry
officeinHaitiandsince1998shehasworkedatWHOHeadquarters,Geneva,inthe
DepartmentofMedicinesPolicy.
InNovember2004,sheinitiatedanddevelopedWHO’sGoodGovernanceforMedi-
cinesprogramme,aimedatpromotinggoodgovernanceandcurbingcorruptioninthe
pharmaceuticalsector.Thisprojectiscurrentlyoperatingin19countriesandisusing
abottom-upapproach,involvingcountryofficialsandinternationalexpertsinthede-
velopmentofnationalgoodgovernanceprogrammesforthepharmaceuticalsector.
37
Name: Mrs. Carole Belisario
Institution: ProcurementWatch,Inc.
Country: Philippines
Ms.CarolineR.BelisarioobtainedherAccountancyDegreeattheHealdBusinessCol-
legeinSanFrancisco,CaliforniaU.S.A.ShehasbeenworkingatProcurementWatch,
IncorporatedinthecapacityasSupervisingTechnicalOfficersince2001andafree-
lanceGovernance/ProcurementConsultant.
Some of her involvement in the area of Governance include Good Governance for
MedicinesProgrammeoftheWorldHealthOrganization,ProcurementAssessmentof
sixteen(16)LocalGovernmentUnitsfortheHealthSectorPolicySupportProgramme
oftheEuropeanUnionCommission,DifferentialExpenditureandEfficiencyMeasure-
mentToolforTAF-USAID,andpromotinggreatertransparencyandaccountability in
thehealthsectorthroughtheMedicinesTransparencyAlliance(MeTA)Council.
38
Name: Mr. Anthony Boni
Institution: UnitedStatesAgencyforInternationalDevelopment(USAID)
Country: UnitedStatesofAmerica
AnthonyBoniisaPharmaceuticalManagementSpecialistintheOfficeofHealth,Infec-
tiousDiseasesandNutritionoftheGlobalHealthBureauoftheU.S.AgencyforInter-
nationalDevelopment(USAID).HehasdesignedandmanagestheAgency’sworldwide
technicalassistanceprogrammesinpharmaceuticalmanagement,druginformationand
medicinesqualityassurance. Hisnewprogramme,StrengtheningPharmaceuticalSys-
tems,hasimprovinggovernanceinthepharmaceuticalsectorasamajorobjective.
Mr.Boni has direct involvement in the implementationofHIV/AIDS,malaria, TB,
maternalandchildhealth,andantimicrobialresistance(AMR)programmesinmorethan
30countries,andhascollaboratedwithallinternationalorganizationsandinitiatives
workinginthepharmaceuticalarea.HealsoconsultedwiththeGlobalFundtoFight
AIDS,MalariaandTuberculosis(GF)regardingqualityassuranceissues,workedwiththe
procurementteamonsupplychainassessmentmethodologies,andmanagesUSAIDtech-
nicalassistancetoGFrecipientstoremovebottlenecksimpedingtheimplementationof
countryprogrammes.
AtechnicaladvisortotheU.S.Government,heprovidesguidanceonpharmaceutical
managementandprocurement,qualityassuranceandprequalificationissues,accessto
andtherationaluseofmedicines,IPRandpatents,andAMR.Withregardtothelatter,
hedraftedtheAMRcomponentofUSAID’sInfectiousDiseaseStrategyandisresponsible
forUSAID’sportfolioofAMRactivities.InhisAMRrole,heprovidedtechnicalandfi-
nancialsupporttotheWorldHealthOrganizationforthedevelopmentoftheWHOGlobal
StrategyfortheContainmentofAntimicrobialResistance.Heisalsoamemberofvarious
internationaltaskforces,includingtheGlobalFund/UNITAIDTechnicalAdvisoryGroup
andtheUnitedStatesPharmacopeiaInternationalHealthExpertCommittee.
PriortojoiningtheHealthOffice,hehelpedsetuptheAgency’scentralizedprocure-
mentanddistributionsystemsforcontraceptivecommoditiesandmanagedtheprovision
oftechnicalassistanceinlogisticsmanagementtoUSAID-supportedprogrammes.
39
Name: Dr. Socorro Escalante
Institution: WorldHealthOrganizationRegionalOfficefortheWesternPacific
Country: Philippines
DrSocorroZarateEscalanteiscurrentlytheProgrammeOfficerforPharmaceuticalsat
theWorldHealthOrganizationOffice inthePhilippines.Sheisamedicaldoctorby
profession,hasalawdegreeandaMastersinBusinessAdministrationinHealthfrom
theAteneoGraduateSchoolofBusiness(AteneodeManilaUniversity).
DrEscalantewasanelectedmemberoftheProvincialBoardofLaUnionfornine
years,andassuchchairedtheCommitteesonHealth,EthicsandGoodGovernmentand
SocialWelfareandDevelopment.Shehasextensiveexperienceoflocalgovernance,lo-
calhealthsystemsandpharmaceuticalmanagementatthelocallevel.Priortojoining
WHO,shealsoworkedwiththeCentreforHealthDevelopment-IoftheDepartmentof
Health.
40
Name: Dr. Sonja Füsser
Institution: FederalMinistryofHealth,Bonn,Germany
Country: Germany
SonjagraduatedfromCologneUniversitywithadegreeinlaw.SheholdsaPhDinlaw
andisaspecialistinthefieldofsocialsecurityandhealthsystem.
Sonja started her career with the German Federal (Social) Insurance Authority
(Bundesversicherungsamt)where shedealtwith legal problemswhicharise in con-
nectionwiththeauthorizationproceduresoftheDiseaseManagementPrograms.In
2005SonjajoinedtheGermanFederalMinistryofHealthasdeskofficer(Referentin)
anddeputydirector.HerareaofresponsibilityisthesupervisionoftheFederalSelf-
GovernmentBodies,theimplementationofanewreformlegislationandtheregulation
ofpharmaceuticalspendinginthestatutoryhealthinsurancesystem.FromSeptember
2005toMarch2006SonjaworkedfortheEuropeanCommission,Directorate-General
HealthandConsumerProtection.
41
Name: Mr. Jim Gee
Institution: KPMGForensic
Country: UnitedKingdom
Jim Gee hasmore than 25 years operational, policy and strategic experience as a
counterfraudspecialistoperatingintheUKincentralgovernment,localgovernment
andtheNHS.
After8yearsheadingupcounterfraudworkinLondonlocalauthoritiesandadvising
theAssociationofLondonGovernment,hejoinedtheDepartmentofHealthin1998
asDirectorofCounterFraudServices,toadvisetheMinisterofStateforHealthandto
establishandheadthenewNHSCounterFraudService(NHSCFS).In2003hebecame
ChiefExecutiveOfficeroftheNHSCounterFraudandSecurityManagementService.
Between2000and2006theNHSCFShasfinanciallybenefitedtheNHStothetune
ofaround£811million–a12:1returngeneratedfroma£67millionbudget.Fraud
losseswerereducedbyupto60%.TheNHSCFSalsohasa96%successfulprosecution
rateandhasneverlostacivillegalcaseonfraud.In2003hisremitwasexpanded
tocoversecuritymanagementintheNHSandtoensuretheproperprotectionofNHS
staff,patients,resourcesandproperty.Sincethattimehehassucceededinreducing
assaultsagainststaffforthefirsttime.
In 2005 he became Director-General of the new EuropeanHealthcare Fraud and
CorruptionNetwork(EHFCN),anorganizationwhichhehelpedfoundin2004.Atthe
foundingconference,organizationsfrom29countriesunanimouslyagreedtheEuro-
peanHealthcareFraudandCorruptionDeclaration.
Since2005,JimhasbeenamemberoftheUKGovernment’sFraudReviewSteering
GroupwhichdevelopedtheUK’sfirstcross-economycounterfraudstrategy.Thisisnow
beingimplementedbyGovernmentandtheUKAttorney-Generalaskedhimtochairthe
FraudReview’sStakeholderGroupandWorkingGrouponFraudLossMeasurement.
Atthestartof2007,hejoinedKPMGForensicasitsDirectorofFraudServices,with
aremittodeveloptheholistic,professionalapproachhepioneeredintheNHS,and
toofferahigh-quality,integratedservicedesignedtoaccuratelyidentifyandreduce
fraudlosses.HehassincedeliveredthisservicetotheNewZealandMinistryofHealth
andiscurrentlyindiscussionswithcolleagueinCanadaandSouthAfrica.
42
Name: Dr. Hans V. Hogerzeil
Institution: WorldHealthOrganization
Country: Switzerland
HansV.HogerzeilMD,PhD,DSc,FRCPEdin.qualifiedasamedicaldoctorfromLeiden
UniversityintheNetherlandsandreceivedaPhDinpublichealthin1984.Forfive
yearshewasamissiondoctorinIndiaandGhanaandin1985hejoinedtheWHOAc-
tionProgrammeonEssentialDrugs,firstintheRegionalOfficefortheEasternMediter-
raneaninAlexandria,andlaterinWHO’sHeadquartersinGeneva.Asastaffmemberof
WHOhehasadvisedmorethan40developingcountries,especiallyinAfricaandAsia,
onthedevelopmentoftheirnationalmedicinespolicy,essentialdrugslistandessen-
tialdrugsprogramme.AsSecretaryoftheWHOExpertCommitteeontheSelectionand
UseofEssentialMedicinesheinitiatedtherecentchangesinproceduresforupdating
theModelListofEssentialMedicines,withstrongeremphasisonevidence-basedselec-
tions.Heestablishedtheweb-basedWHOEssentialMedicinesLibraryandisoneofthe
editorsoftheWHOModelFormulary2006.
InhispositionasDirectoroftheDepartmentofMedicinesPolicyandStandardshe
istechnicallyresponsibleforallWHO’sglobalpolicies,normsandstandardsonmedi-
cines.HeisalsotheChairoftheInteragencyPharmaceuticalCoordinationGroupwhich
coordinatesthepharmaceuticalpoliciesandprogrammesofallmajorUNagencies,the
GlobalFundandtheWorldBank.
DrHogerzeilistheeditorofseveralWHObooksonessentialmedicinespolicies,the
qualityuseofmedicines,medicinesinemergencysituationsandessentialmedicines
forreproductivehealth.Hehaspublishedover50scientificpapersinpeer-reviewed
journalsandteacheseveryyearatinternationalcoursesallovertheworld.In1996he
wasinvitedtobecomeaFellowoftheRoyalCollegeofPhysiciansinEdinburghandin
1998hereceivedanhonoraryDoctorateofSciencefromtheRobertGordonUniversity
inAberdeen,Scotland.Heismarriedwithfourchildren.
Hisrecentinterestsincludeessentialmedicinesforreproductivehealth,andaccess
toessentialmedicinesaspartofthefulfilmentoftherighttohealth.
43
Name: Mr. Martin Kreutner
Institution: FederalBureauforInternalAffairs,FederalMinistryoftheInterior
Country: Austria
Bornin1964;studiedlawattheUniversityofInnsbruck.Commissionedofficerinthe
AustrianArmedForceswithvarioustroop,staffandministerialassignments;serveda
totaloffiveyearswithdifferentUNandNATOmissionsinSyria,Israel,Lebanonand
Albania.In2000,hetransferredtotheAustrianFederalMinistryoftheInteriorand
wascommissionedtobuildupananti-corruptionserviceunit(BIA);since2001heads
theAustrianFederalBureauforInternalAffairs(BIA);2004obtainedanadditional
degreeasMasterofScienceinPolicingandPublicOrderStudiesattheUniversityof
LeicesterinU.K.;guest-lecturedoninternationalhumanitarianlawattheGermanRed
Cross,aswellastheRuhrUniversityinBochum,Germany;healsolecturedongeneral
andspecialsecurityandanti-corruptiontopicsatseveralEuropeansecurityandmili-
taryacademiesaswellasuniversities.Inthecourseofhisworkhehasspokenwidely
atinternationalconferences–interalia–inBrazil,Canada,China,HongKong,Jordan,
ThailandandthroughoutEurope.
MemberofInterpol’sInternationalGroupofExpertsonCorruption,memberofthe
ExecutiveCommitteeoftheEuropeanHealthcareFraudandCorruptionNetwork,EH-
FCN,memberoftheAdvisoryBoardtoTransparencyInternational–ChapterAustria,
jurortotheSpeyererQualityCompetitiononCorruption,wasputinchargeofcorrup-
tionissuesbytheWorldBank;heisacourtexpertongeneralcriminologyaswellas
VIPprotection,inadditiontobeingchairmanoftheSupremeDisciplinaryCommission
oftheFederalMinistryoftheInteriorandmemberoftheFederalAppealsTribunal;
authorofmanyarticlesandpapersonsecurityissues,editorofabookoncorruption
(2006)andco-authorofalegalcommentary(2005).
MartinKreutnerhasmaintainedarelationshipwithhispartner,apharmacist.He
lovessports,musicandnature.
44
Name: Dr. Kerstin Leitner
Institution: WorldHealthOrganizationGGMGlobalAdvisoryGroup
Country: Germany
KerstinLeitnerearnedherPhDwithathesisonsocio-economicdevelopmentinKenya
atBerlin’sFreeUniversityinhernativeGermanyin1975.Ayearlatersheembarked
onwhatwastobecomea27yearcareerwiththeUNDevelopmentProgramme(UNDP).
SheheldseveralpostsinAfrica,Asia,EuropeandtheMiddleEast.Mostrecently,from
1998until2003,shewasUNResidentCoordinatorandUNDPResidentRepresentative
inChina.Beforethat,from1997–1998,shewasSeniorSpecialAdvisertotheUNDP
AssistantAdministratorandDirectorinAsiaandthePacific.
InSeptember2003,shebecameAssistantDirector-GeneralofWHO’sSustainableDe-
velopmentandHealthyEnvironmentsClusterofdepartments.Herteamhassharpened
itsfocusonprovidinginformationandknowledgetonumerousWHOMemberStateson
thepublichealthimpactofenvironmentalfactors.
45
Name: Dr. Maureen Lewis
Institution: TheWorldBank
Country: UnitedStatesofAmerica
Maureen Lewis is Chief Economist,HumanDevelopment at theWorld Bank encom-
passinghealth,educationandsocialprotection.Muchofherresearch,publications
andpolicyworkexaminegovernanceandefficiencyinthesocialsectors,particularly
health. ShewasformerlyaSeniorFellowattheCenter forGlobalDevelopmentfor
twoyearsandpriortothatmanagedaunitintheWorldBankdedicatedtoeconomic
policyandhumandevelopmentresearchandprogramsinEasternEuropeandCentral
Asia.BeforejoiningtheWorldBank,sheestablishedandoversawtheinternational
healthpolicyagendaatTheUrbanInstitute.Shehaspublisheddozensofarticlesin
peer-reviewedjournalsonarangeoftopicsinthesocialsectors.SheearnedherPhD.
atJohnsHopkinsUniversity.
46
Name: Mr. Changyuan Lin
Institution: StateFoodandDrugAdministration
Country: People’sRepublicofChina
Mr.ChangyuanLinisaprincipalstaffmemberoftheGeneralOfficeintheStateFood
andDrugAdministration(SFDA),PRC,whereheisresponsiblefordraftingpolicyre-
portsandspeechesthatneedtobedeliveredbytheCommissioner.BeforeJoiningthe
SFDAin2004,hehadbeenaresearcherandassistantprofessorfor4yearsintheLaw
Institute,oftheChineseAcademyofSocialSciences.Alawyer,Mr.ChangyuanLinhas
bothbachelorandmastersdegreesinlawandwasawardedapostgraduatediploma
withdistinctionbyLondonUniversityin2003.
47
Name: Dr. Maria Miralles
Institution: ManagementSciencesforHealth’sRational
PharmaceuticalManagement(MSH)
Country: UnitedStatesofAmerica
Dr.MariaMirallesistheDeputyDirectorforManagementSciencesforHealth’sRatio-
nalPharmaceuticalManagement(RPM)PlusProgramaswellastherecentlyawarded
StrengtheningPharmaceuticalSystems(SPS)ProgramandisbasedinArlington,Vir-
ginia.Shehasmorethan25yearsofexperience inpublichealthand international
development,halfofthemwithafocusonpharmaceuticalmanagement.Withastrong
backgroundinoperationsresearch,researchdesignandmethodology,andmonitoring
andevaluation,shehasworkedinallaspectsofpharmaceuticalsystemsandsupply
management.WithRPMPlusandSPS,Dr.Mirallesoverseesprogrammesinmorethan
20countries.Sheguidesthedevelopmentandimplementationofappropriatephar-
maceuticalmanagementmechanisms and systems based on best practices and the
principlesofgoodgovernancetoincreaseaccesstoqualityessentialmedicinesand
enhancetheeffectivenessofhealthcaresystems.SheholdsaPhDinPharmacyHealth
CareAdministrationinadditiontoaMastersdegreeinAnthropology.
48
Name: Dr. Zafar Ullah Mirza
Institution: WorldHealthOrganization
RegionalOfficefortheEasternMediterranean
Country: Egypt
CurrentlyworkingasRegionalAdviser–EssentialMedicines&BiologicalsattheEast-
ernMediterraneanRegionalOfficeoftheWorldHealthOrganizationinCairo,Egypt,
covering22countries.MedicalgraduatewithMastersinPublicHealth.Specialinter-
est, experience and trainings in drug policy/management issues. Other experience
includespsychiatryandruralhealthservice.In1992establishedanon-profit“Associa-
tionforRationalUseofMedicationinPakistan”latertransformeditintothefirstna-
tionalconsumerorganizationinthecountry:“TheNetworkforConsumerProtection”,
servedasitsfoundingExecutiveDirectorfor12years.Theorganizationisactivein
pharmaceuticals, tobacco,water, unethicalmarketing, consumermobilization, legal
research,consumerredress,tradeissuesrelevanttopublichealth.In1995wonBri-
tanniaScholarshipforMPHinLondonandselectedasEisenhowerFellowfortheyear
2003byEisenhowerFoundation,USA.HasservedonthefacultyofBostonSchoolof
PublicHealthandwaspartofUNMillenniumprojectTaskForce.Servedasmemberof
FoundationBoardofHealthActionInternationalandasmemberofWHOInternational
ScientificAdvisoryGrouponGlobalizationandHealth.LedadelegationofConsumers
International at the 3rd& 4thWTOministerialmeetings in Seattle and Doha. Co-
authoredajointWTO/WHOpublication:“WTOAgreementsandPublicHealth”.
49
Name: Mrs. Rosminah Mohd. Din
Institution: PharmaceuticalServicesDivision,MinistryofHealth
Country: Malaysia
RosminahMohd.DinhasaMastersinMedicalScience(PublicHealth),2003,University
ofMalaya,Malaysia,aswellasaBachelorofPharmacy,1983,SouthAustralianInsti-
tuteofTechnology,Australia.
SheistodayHeadoftheMinistryofHealthDrugFormularyUnit,inthePharmaceu-
ticalServicesDivision.HermainjobfunctionsincludeManagementoftheMOHdrug
formulary,developmentoftheMalaysiandrugcode(MDC),managementofrequestsfor
drugsnotincludedintheMOHformulary,andSecretariattotheNationalDrugFormu-
laryPanel,whichisresponsiblefortheselectionofdrugsforinclusionintheMOHdrug
formulary,NationalEssentialDrugsList(NEDL),pharmacoeconomicsandGGM.
Herareasofinterestsare:drugutilisation,qualityuseofmedicines,pharmacoeco-
nomics,medicationsafetyandgoodgovernance.
50
Name: Ms. Nazarita Tacandong
Institution: WorldHealthOrganizationRegionalOfficefortheWesternPacific
Country: Philippines
Ms.Tacandongisapharmacistbyprofession.ShehasobtainedherBachelorofScience
inPharmacyattheSouthwesternUniversity,CebuCity,Philippines.Shepursuedher
studiesandgraduatedwithaMastersinPublicAdministration.MsTacandongisashort
termprofessionalattheWorldHealthOrganization,WesternPacificRegionalOfficein
Manila.
She has beenwith the Bureau of Food and Drugs, the national drug regulatory
authorityofthePhilippines,for29years.Shehastakentheleadinthefightagainst
counterfeitdrugsinthecountry.Assuch,shehasbeeninvitedasresourcespeaker/
lecturertomanyconferences,bothlocalandinternational.
ShewasresponsiblefortheimplementationofGoodManufacturingPractices(GMP)
forpharmaceuticalestablishmentsandlaterforcosmeticestablishments,andeventu-
allyforthedraftingofGMPguidelinesforfoodestablishments.
Ms.TacandonghasrecentlyreceivedtheAWARDOFEXCELLENCEfromthePhilippine
FederationofProfessionalAssociationsofthePhilippines.InJunethisyear,shewas
awarded“THEPRCOUTSTANDINGPROFESSIONALOFTHEYEAR”inthefieldofPharmacy
andawardedasALUMNIGREATinJanuaryandalsoasOutstandingPharmacistinthe
Governmentin2006.
Ms.TacandonghasbeeninstrumentalinthedevelopmentoftheNationalEthical
InfrastructureforGoodGovernanceinthePhilippines.ShehasrepresentedtheBureau
andthecountryinmeetingsongoodgovernance.
51
Name: Dr. Eric Noehrenberg
Institution: InternationalFederationofPharmaceuticalManufacturers
&Associations(IFPMA)
Country: Switzerland
Dr.EricNoehrenbergisDirectorofInternationalTradeandMarketIssuesattheIn-
ternationalFederationofPharmaceuticalManufacturers&Associationsandhasheld
thispositionsinceOctober1999.Inthiscapacity,Dr.Noehrenbergisresponsiblefor
negotiations regarding trade andmarket issuesbetween theglobal, research-based
pharmaceuticalindustryandthemajorinternationalorganizationsinvolvedinthese
issues, including the, theWorldHealthOrganization (WHO), theWorld TradeOrga-
nization(WTO),andtheWorldIntellectualPropertyOrganization(WIPO).Heisalso
responsibleforAIDSissues,bioterrorismconcerns,andInternetmatters.
Prior to joiningIFPMA,Dr.NoehrenbergwasanExternalRelationsOfficer in the
unitofDonorandCorporateRelations,JointUnitedNationsProgrammeonHIV/AIDS
(UNAIDS),from1996toOctober1999.Dr.NoehrenbergwasaProjectManageratthe
WorldEconomicForumfrom1994to1996,wherehewasresponsibleforthedevelop-
mentoftheGlobalGrowthCompaniesmembership,aswellasforcoordinatingForum
eventsinSingapore,theMekongSubregionandChicago.
Dr.Noehrenbergbeganhiscareerinthehealthfieldasapolicyanalystinthede-
partmentofPharmaEconomicsandPolicyatCIBA-GEIGY(nowNovartis)headquarters
inBasel.
Dr.Noehrenberggraduatedwithadoctoratecum laudefromtheUniversityofTübin-
gen,Germany.Heearnedhismaster’sdegreewitha concentration in International
TradeandFinance fromHarvardUniversityandhisBachelorofArts fromPrinceton
University.
52
Name: Dr. Clive Ondari
Institution: WorldHealthOrganization
Country: Switzerland
CliveOndarihasover20yearsofexperienceinpharmaceuticalpoliciesandprogrammes,
havingworkedfortheGovernmentofKenyaandWHOonvariousassignments.Heholds
aDoctorateinPharmaceuticalSciencesandMasterofScienceinBusinessAdministra-
tion(StrategicPlanning).Hestartedhiscareerinacademiaandregulatoryaffairsin
KenyawherehewasAssociateProfessorandHeadofDepartmentattheUniversityof
NairobiandChairmanofthePharmacyBoard(CommitteeonRegistrationofMedicines)
forover10years.
Forthelast2years,hehasbeentheCoordinatorforMedicinesPolicy,Accessand
RationalUse,whichincorporatesWHOHeadquarter’sguidanceworkonnationalmedi-
cinespolicies,selection,suppliesmanagementandrationaluseofmedicines.
53
Name: Dr. Steven Rood
Institution: TheAsiaFoundation
Country: Philippines
StevenRoodisTheAsiaFoundation’scountryrepresentativeforthePhilippinesand
PacificIslandNations.InhisconcurrentroleasRegionalAdvisorforLocalGovernance,
hehelpstobuildlocalgovernment,decentralization,andmunicipalgovernmentpro-
grammesthroughouttheregion.Dr.Rood,anexpertonlocalgovernment,decentral-
ization,andpublicopinionpolling,hasbeenaconsultanttobothgovernmentand
nongovernmentalorganizations,includingAssociatesinRuralDevelopmentInc.,The
SocialWeatherStationsinManila,andUSAID.Dr.RoodservedasprofessorofPolitical
ScienceattheUniversityofthePhilippinesCollegeBaguiofrom1981until joining
theFoundationin1999,andwastheonlyforeignfacultymemberwithtenureinthe
UniversityofthePhilippinessystem.
Dr.RoodistheauthorofanumberofworksonFilipinopolitics,withaspecialfocus
ondemocracyanddecentralization.HismostrecentpublicationisForging Sustainable
Peace in Mindanao: The Role of Civil Society(East-WestCenterWashington,PolicyStud-
ies17,2005);
Education:B.A. inpoliticalscience,UniversityofWashington;M.A.andPh.D. in
politicalsciencefromBostonUniversity.
54
Name: Dr. Tsetsegmaa Sanjjav
Institution: HealthSciences,UniversityofMongolia
Country: Mongolia
ProfessorSanjayhasaPh.Dinpharmacy.SheisalsoDeanoftheSchoolofPharmacy,
HealthSciencesattheUniversityofMongoliainUlaanbaatar.
55
Name: Mrs. Fatuma Sichale
Institution: KenyaAnti-CorruptionCommission(KACC)
Country: Kenya
Mrs.FatumaSichaleistheDeputyDirector/AssistantDirectorin-chargeoftheLegal
ServicesDirectorateattheKenyaAnti-CorruptionCommission.TheKenyaAnti-Corrup-
tionCommissionisastatutorybodysetuptospearheadthefightagainstcorruption
inKenya.ShewasappointedtothispositioninSeptember2004.
Prior toherappointmentasanAssistantDirector,Mrs.Sichalewas inprivate legal
practice.Herpracticeofthelawspansaperiodofover20years.Shehadalsohada
shortstintatthejudiciarywheresheresignedatthelevelofResidentMagistrateto
enterintothecompetitiveworldoflegalpractice.
Besidesworking in the judiciaryandher legalpractice,Mrs. FatumaSichalehas
servedinothercapacitiesi.e.
i) ShewasoneofthesevenBoardMembersofthedefunctKenya
Anti-CorruptionAuthority.
ii) AdvisortotheKenyaAnti-CorruptionPoliceUnit,abodythatreplacedthe
defunctKACA.
iii) CouncilMember,LawSocietyofKenya.
iv) CouncilMemberoftheFederationofWomenLawyers(FIDA)KenyaChapter.
v) BoardMember,KenyaAnti-CorruptionCommissionbeforeresigningto
competitivelyapplyforthepositionofanAssistantDirector,LegalServices.
Mrs.SichaleholdsaBachelorofLawdegreefromtheUniversityofNairobiandaDi-
plomainLawandPracticefromtheKenyaSchoolofLaw.Sheisanadvocateofthe
HighCourtofKenya.
56
Name: Dr. Sri Suryawati (Surya)
Institution: CentreforClinicalPharmacologyandMedicinesPolicyStudies,
GadjahMadaUniversity
Country: Indonesia
Dr.SriSuryawati(Surya)isActingDirectoroftheCentreforClinicalPharmacologyand
MedicinesPolicyStudies,andCoordinatoroftheMasterDegreeProgramforMedicine
PolicyandManagement,GadjahMadaUniversity.
SheisamemberoftheUNInternationalNarcoticsControlBoard.ExecutiveBoard
oftheInternationalNetworkforRationalUseofDrugs(INRUD),andtheWHOExpert
AdvisoryPanelforMedicinePolicyandManagement.SheisalsoaWHOExpertCommit-
teememberfortheSelectionandUseofEssentialMedicines(since2002),WHOExpert
CommitteememberfortheMedicinesCausingDependency(2002-2005),andamember
oftheUNMillenniumProject:MillenniumDevelopmentGoalTaskForce5onHIV/AIDS,
TB,Malaria,andAccesstoEssentialMedicines.
Herareasofworkincludemedicinespolicyandpromotingthequalityuseofmedi-
cines(since1990),drugevaluationandnewdrugapplication(since1987),andclini-
cal pharmacokinetics and bioequivalence testing (since 1984). Since 1996 she has
supervised>100master anddoctoral thesesonclinicalpharmacokinetics,medicine
policy,medicinesupplymanagement,andimprovingmedicineuseinhealthfacilities
andthecommunity.
Shealsoworksasaninternationalconsultantonessentialmedicineprogrammes,
promotingrationaluseofmedicines,medicinepolicy,drugevaluation,bioequivalence
testing,aswellasbeingaFacilitatoronvariousinternationaltrainingcourses,e.g.
onPromotingRationalUseofMedicines,HospitalDrugandTherapeuticsCommittees,
andMedicinePolicyIssuesinDevelopingCountries.
57
Name: Dr. Chanvit Tharathep
Institution: BureauofHealthServiceSystemDevelopment,
HealthServiceSupportDepartment,
MinistryofPublicHealth.
Country: Thailand
Dr.MD.ChanvitTharathep,FRCST(FellowoftheRoyalCollegeofSurgeonsThailand),
Diploma of FamilyMedicine Thailand, is the Director of theHealth Service System
DevelopmentBureauinThailand.
Other experiences: system analysis, hospital information systems, diagnostic-
relatedgroupresearchawards:
1. Peritoneovenousshuntforascites;Preliminaryreport.
2. ComputerbasedinformationsystemforORregister.
3. Re-engineeringoftheOutPatientDepartment.
4. Peritoneovenousshuntforascitesormedicaltreatment,aprospective
comparativestudy.
CurrentResponsibilities:
• ProjectaboutautonomoushospitalsinThailand.
• Implementationofdiagnostic-relatedgroup(DRG).
• HospitalinformationsystemandotherinformationintheProvincial
HospitalDivision.
• Financingandbudgetingforhospitals.
• PharmacyInformationCentre.
58
Name: Dr. Sirinart Vasanavathana
Institution: OfficeofFoodandDrugAdministration,
MinistryofPublicHealth
Country: Thailand
Education:
B.Sc.inPharmaceuticalSciencefromFacultyofPharmacy,Mahidol
University,Bangkok,Thailand
M.S.andPh.DinMedicinalChemistry,CollegeofPharmacy,TheOhioState
University,Columbus,Ohio,U.S.A.
Experience:
Reviewquality,efficacyandsafetyofpharmaceuticalproductssubmittedforregistra-
tioninThailand.ReviewethicalandscientificissuesfortheEthicsCommitteeofthe
MinistryofPublicHealth,Thailand.Co-developmentofguidelinesonbioequivalence
studies,GCPinThailandandWHOGMPforRadiopharmaceuticals,developmentofand
traininginStandardOperatingProceduresforEthicalReviewCommitteesinAsiaand
thewesternPacificregion.Co-editorandawriterofarticlesforThaiFDAandSafety
BulletinofHealthProductsJournals.Consultantonregistrationrequirementsforphar-
maceuticalproductsduringresearchanddevelopment.Proceedingonreductionand
phase-outofpharmaceuticalproducts(MeteredDoseInhalers)containingCFC.Survey
andevaluationofSIDCER-FERCAPqualityonethicalreviewprocessofIEC/IRBcommit-
tee.InspectionandevaluationofmanufacturingplantsforGMPCompliance.Traineron
qualitymanagement,processvalidationandgoodlaboratorypractice.
59
Name: Mr. Paul Vincke
Institution: EuropeanHealthcareFraudandCorruptionNetwork(EHFCN)
Country: Belgium
PaulVinckewasTreasurerandDeputyDirector-GeneralfromOctober2005,beforebe-
ingnominatedPresidentoftheEuropeanHealthcareFraudandCorruptionNetworkin
October2007.
Inthisnewfunctionhewishestocontinuehiseffortsbycommittinghimselffully
toestablishingaNetworktoberecognizedandappreciatedforplayinganimportant
roleandprovidingrealaddedvalueincounteringfraudandcorruptioninhealthcare
inEuropeandelsewhere.
By profession Paul Vincke is Director of Staff at the Service of Medical Evalua-
tionandControl(SECM)oftheNationalInstituteforHealthandDisabilityInsurance,
Belgium(INAMI).
HehasadegreeinCriminologyfromtheKatholiekeUniversiteitLeuven.
AfterbeingwiththeNationalPensionfundforMinersasaFinancialandPersonnel
Directorfor14years,hejoinedtheSECMoftheINAMIin1999becomingDirectorof
Staffresponsibleforpersonnel,organizationandgeneralpolicy.Asamemberofthe
managementteamheisdirectlyinvolvedinthereorganizationoftheService,aiming
atthedevelopmentofhighlyefficientsystemsandtoolsofevaluation,prevention,
detectionandinvestigationofallegedimproperuseoftheFederalhealthcareresources
byhealthcareproviders.Thisshouldresultinactivesurveillanceofgoodmedicalprac-
ticeandtheimpositionofappropriatesanctions.
60
Name: Mr. Eshetu Wondemagegnehu
Institution: WorldHealthOrganizationGGMGlobalAdvisoryGroup
Country: Ethiopia
MrEshetuWondemagegnehuisanEthiopianbynationality.HeholdsB.Pharm.andMSc
degreesinPharmacyandPharmaceuticalQualityControlrespectively.Hehasworkedfor
theEthiopianGovernmentindifferentcapacities,includingasheadoftheDrugControl
andToxicologyLaboratoryattheInstituteofPasteurinAddisAbaba,Ethiopia,forover
nineyearsandasheadoftheDrugControlDepartmentoftheMinistryofHealthofEthiopia
for12years.From1993to2006heworkedforWHO,Geneva,asaTechnicalOfficerinthe
DepartmentofEssentialDrugsandMedicines(EDM).
WhileatWHO,MrEshetu’smainworkwasbuildingmedicineregulatorycapacityand
training regulatoryofficers inAfrica,AsiaandotherWHOregions;collaborating in the
developmentofWHOnormsandguidelinesforensuringthequality,safetyandefficacyof
medicines;carryingoutoperationalresearchtoassessthestatusofmedicinesregulationin
MemberStates;developingWHOpolicydocumentsintheareaofmedicineregulationand
qualityassurance;promotingsub-regionalandregionalharmonizationofmedicineregula-
tion;combatingcounterfeitandsubstandardmedicines;trainingmedicineregulatorsand
otherlawenforcementauthoritiesondetectionandinvestigationofcounterfeitmedicines;
enhancinginter-country,regionalandinterregionaltechnicalcooperationtopromoteef-
fectivedrugregulation;developingtoolsforassessingmedicineregulationbettermanage-
mentandimplementationofqualityassuranceandregulatorymechanisms;andpromoting
awarenessamongthepublic,highleveldecision-makersandpoliticians,healthprofession-
als,etc.oftheneedforeffectivemedicineregulation.MrEshetuhasalsobeenactivein
conductingfieldstudiesandinthepublicationofWHOguidelinesanddocuments.
Inconnectionwithhisworkhehastravelledtoover60countriesinAfrica,Asia,Eu-
rope,NorthAmericaandthePacifictoorganizetrainingcourses,providetechnicalsupport
andmakepresentationsonissuesrelatedtoeffectivemedicineregulationandcounterfeit
medicines.
AtpresentheworksasaPharmaceuticalConsultant.HeisalsoamemberoftheWHO
ExpertCommitteeonSpecificationsforPharmaceuticalPreparationsandtheGGMGlobal
AdvisoryGroup.
64
Evaluation Form Yourexperienceatthisstakeholdersmeetingisimportanttous.Pleasetakeafewmo-
mentstocompletethefollowingevaluationtogiveusyourviewsonthemeetingand
whatwecandobetteratfuturemeetings.
Name
Institution
Panel Sessions and PanellistsForthesessionsyouattended,please
• indicatehowinteresting/relevantthesessioncontentswasforyou/yourinstitution
4=Veryhigh 3=High 2=Good 1=Low
• ratethevalueofthepresentationsandparticipationofthepanellistswithineachsession
4=Excellent 3=Verygood 2=Good 1=Poor
PanelSession1:Thinktransparency!GoodGovernanceinthepharmaceuticalsector.
Overallvalueofthepanelsession 4321
Valueofthepresentationandparticipationofthepanellist
Dr.GuitelleBaghdadi-Sabeti,WHO,Switzerland 4321
Dr.ChanvitTharathep,MinistryofPublicHealth,Thailand 4321
Mr.ChangyuanLin,StateFoodandDrugAdministration,China 4321
Mrs.GerganaAndre,InternationalHealthcare 4321
andHealthInsuranceInstitute,Bulgaria
65
PanelSession2:Therootofcorruption.Understandingtheissuestocureit!
Overallvalueofthepanelsession 4321
Valueofthepresentationandparticipationofthepanellist
Dr.MaureenLewis,WorldBank 4321
Mr.MartinKreutner,BureauofInternationalAffairs, 4321
FederalMinistryofInterior,Austria
TransparencyInternationalSecretariat 4321
Dr.StevenRood,AsiaFoundation,Philippines 4321
PanelSession3:Practicingtransparency!GoodGovernanceinthehealthsector.
Overallvalueofthepanelsession 4321
Valueofthepresentationandparticipationofthepanellist
Dr.MaureenLewis,WorldBank 4321
Mr.JimGee,KPMGForensic,UnitedKingdom 4321
Mr.PaulVincke,EuropeanHealthcareFraudand 4321
CorruptionNetwork(EHFCN),Belgium
Dr.EricNoehrenberg,InternationalFederationof 4321
PharmaceuticalManufacturers&Associations
66
PanelSession4:Keepingittogether!ThebasicingredientsforensuringGoodGovernance.
Overallvalueofthepanelsession 4321
Valueofthepresentationandparticipationofthepanellist
Dr.EloyAnello,NùrUniversity,Bolivia 4321
Dr.SonjaFüsser,MinistryofHealth,Germany 4321
Mrs.FatumaSichale,Anti-CorruptionCommission,Kenya 4321
PanelSession5:Questioningtransparency.Ourpanellistsrespondtoyou!
Overallvalueofthesession 4321
PanelSession6:Rollingouttransparency.Whatisyourrole?
Overallvalueofthepanelsession 4321
Valueofthepresentationandparticipationofthepanellist: 4321
Mr.AnthonyBoni,USAID,UnitedStatesofAmerica 4321
Mrs.CaroleBelisario,ProcurementWatchInc.,Philippines 4321
Dr.NiyadaKiatying-Angsulee,ChulalongkornUniversity,Thailand 4321
Dr.ZafarMirza,WHORegionalOfficeforthe 4321
EasternMediterranean,Egypt
67
WorkshopsFortheworkshopsessionsyouattended,pleaseindicatehowinteresting/relevantthesession
topicanddiscussionwasforyou/yourinstitution
4=Veryhigh3=High2=Good1=Low
1.BRIDGINGTHERESEARCHGAP–
whatdowestillneedtoknow,andhowdowegoaboutit? 4321
2.MAXIMIZINGTHEUSEOFINTERNETTOINCREASETRANSPARENCY
how? 4321
3.ESTABLISHINGANATIONALGGMTASKFORCE
whatarethechallengesahead? 4321
4.JOININGFORCESONANATIONALLEVELWITHANTI-CORRUPTIONAGENCIES
whatworks,whatdoesn’t? 4321
5.CANYOUBREAKTHROUGHTHEGIFT-GIVINGCULTURE?
howdowebringtransparencytothegreyzone? 4321
6.DEFININGINTEGRITY
howdoweraisethestandardsandmotivatepermanentchange? 4321
7.WHATRADICALCHANGESWILLTRANSPARENCYBRINGTOTHEPHARMACEUTICALWORLD?
whoaretheplayers?whatwillbetheimpactonpublichealth? 4321
8.SERVINGTRANSPARENCY!
HowcanWHObeofbetterservicewhenfacilitatingGGMprogramme
implementation?Giveyourideasandfeedback. 4321
68
Ratethefollowingaspectsofthemeeting
4=Excellent 3=Verygood 2=Good 1=Poor
Overallvalueofthemeeting 4321
Meetingagenda 4321
Networkingevents 4321
Location 4321
Hotelvenue 4321
Questions:
Whatpanelsessionsandworkshoptopicswouldyouliketoseeatthenextstake-
holdersmeeting?
Howcouldthenextmeetingbeabetterandmorevaluableresourceforyou?
DoyouintendtoattendthenextWHOstakeholdersmeeting? Yes/No
84
WHO'sGoodGovernanceforMedicinesprogrammewaslaunchedin2004.Itiscurrentlyoperatinginnineteencountriesglobally.Theprogramme'sgoal istoreducecorrup-tion inpharmaceuticalsystemsthroughtheapplicationoftransparent,accountableadministrativeproceduresandthepromotionofethicalpractices.Itsultimateaimistoensurethatessentialmedicinesreachpeople–nottheblackmarket.
WHOisgratefultotheGermanFederalMinistryforEconomicCooperationandDevelop-ment(BMZ)foritsfinancialsupport,withoutwhichthismeetingcouldnothavebeenheld. Additionalinformation:http://www.who.int/medicines/ggm [email protected]